Canaccord lowered the firm’s price target on Adicet Bio to $21 from $28 and keeps a Buy rating on the shares. The firm noted Adicet has initiated the Phase 1 EXPAND cohort in post-CART Large B-Cell Lymphoma (LBCL) using lead asset, ADI-001. After undergoing a strategic review of the pipeline, the company will focus efforts on ADI-270 in renal cell carcinoma (RCC) with IND expected 1H24.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACET:
